Company Profile
Covance
Company Overview
Covance, the drug development business of LabCorp, is the world’s most comprehensive drug development services company. Because of our broad experience, from early research to commercialization, our more than 20,000 employees from across the globe are in a unique position to supply insights that go above and beyond testing. Our team’s impact on healthcare is remarkable. Through their everyday work they’ve supported 100% of the top 50 drugs on the market and all the oncology drugs approved in 2016. Even though we span multiple businesses, we operate as one, sharing our knowledge to improve our efficiency and deliver on the promise of a healthier world.
The Covance team is driven by an energized purpose to improve health and improve lives across the globe. Here, you’ll work alongside exceptional people who each play an important role in bringing new scientific discoveries and therapeutic area advancements to life. And, because we span the drug development spectrum, you’ll directly impact a wide-range of initiatives as you explore unique career paths and discover your extraordinary potential.
Get ready to make a difference as we speed the delivery of groundbreaking therapies and improve lives of countless individuals.
Company History
2015: LabCorp® (NYSE: LH) acquires Covance Inc., creating the world’s leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to-end solutions for drug and diagnostics development and commercialization.
2011: Takeda Pharmaceuticals International, Inc. chooses Covance as one of its strategic partners to plan and execute global development programs to support new compounds in all therapeutic areas, except oncology.
2010: Covance signs landmark agreement with Sanofi-Aventis for a 10-year strategic R&D alliance and acquires their Porcheville, France and Alnwick, United Kingdom sites.
2009: Covance acquires Merck's Seattle-based Gene Expression Laboratory. Under the agreement, Merck has committed to a five-year $145 million contract to purchase genomic analysis services from Covance. Covance acquires Swiss Pharma Contract, a clinical research company based in Basel, Switzerland.
2008: Covance purchases minority equity stake in Caprion Proteomics, the leading provider of proteomics-based services to the pharmaceutical industry, to further enhance its biomarkers service offering to clients. Covance makes CRO history with the most comprehensive drug development partnership in the industry. Covance acquires Lilly’s Greenfield, Indiana campus and executes a 10-year service agreement with Lilly.
2007: In celebration of their 10-year anniversary, Covance announces our partnership with CARE to support the Covance-CARE Early Childhood Development (ECD) Initiative for Orphans and Vulnerable Children in Rwanda. Covance opens Central Labs facility in Shanghai, China.
2006: Covance announces acquisition of eight early phase clinical pharmacology sites of Radiant Research, Inc. Opens the largest toxicology expansion in Madison, Wisconsin.
2002: Covance acquires Virtual Central Labs, now known as Local Laboratory Services.
2000: Central STET laboratory opens in Singapore to serve fast-growing East Asian market. Covance expands pharmaceutical analysis facility in Harrogate, U.K. and Phase I clinical research unit in Leeds, U.K.
1998: Covance acquires the Berkeley (California) Antibody Company.
1997: Covance begins operations as an independent, publicly traded company on the New York Stock Exchange (NYSE) after our official spin-off from Corning Incorporated